 There are many vaccines in the pipeline now for COVID-19, and several are poised to enter the clinic following approval. But, Dr. Kanichi Masuda, a veterinarian who studies immunology at the Rikin Baton Zone Program, is working to develop a new type of vaccine. He has studied the phenomenon of zoonosis, where pathogens like the virus that causes COVID-19 move between species, and is using this knowledge to tackle the pandemic. According to Dr. Masuda, pathogenic coronaviruses have a special talent that makes them particularly dangerous. Those virus can infect the immune cells. Immune cells release lots of inflammatory agents, which cause very severe inflammation. In addition, immune system moves all the body over the body, therefore they will cause severe inflammation systemically. This makes a vaccination strategy difficult. Dr. Masuda warns that under certain conditions, mutated viruses might trigger antibody-dependent enhancement even after vaccination with current vaccines. So what can be done? The vaccine I'm doing is very special for the mutated viruses. The virus changes their surface protein, their body, very frequently. Once they change their bodies, the current processing developing vaccine would not be effective to prevent those virus infections, so that I am looking at a very conserved region, which means a common region among all the coronaviruses. Using this region, I am developing a new strategy of the vaccine to induce a new type of antibody against this specific region. At present, Dr. Masuda's team is working on experiments to develop a new vaccine. At present, Dr. Masuda's team is working toward a COVID-19 vaccine, but the approach could go beyond that. I'm working on the new type of vaccine against COVID-19, but this concept will be applicable for other viruses such as Ebola, hemorrhage viruses, and also the Deng hemorrhage virus. Those viruses have similar genesis, which means that they can affect the macrophages.